TAK-390MR: Phase III data

In a double-blind, international Phase III trial in 2,046 patients with Grade A-D erosive esophagitis, 60 and 90 mg doses of TAK-390MR met the primary endpoint of non-inferior healing rates vs. 30 mg ...